inclusion criteria: * admitted covid-19 patients being treated as an in-patient at a hospital facility. * covid-19 diagnosis confirmed by pcr nasopharyngeal swab. * study participants must be symptomatic with any covid-19 symptoms defined by the bahrain national protocol * onset of symptoms must be within 10 days prior to enrolment. * study participants must have the ability to give informed consent. * participants must be at minimum 21 years of age. * mild to moderate covid-19 disease defined as saturation equals to or more than 93% on room air or pao2:fio2 ratio more than 300 on enrolment.

inclusion criteria: * admitted covid-19 patients being treated as an in-patient at a hospital facility. * covid-19 diagnosis confirmed by pcr nasopharyngeal swab. * study participants must be symptomatic with any covid-19 symptoms defined by the bahrain national protocol * onset of symptoms must be within 10 days prior to enrolment. * study participants must have the ability to give informed consent. * participants must be at minimum 21 years of age. * mild to moderate covid-19 disease defined as saturation equals to or more than 93% on room air or pao2:fio2 ratio more than 300 on enrolment.

inclusion criteria: - admitted covid-19 patients being treated as an in-patient at a hospital facility. - covid-19 diagnosis confirmed by pcr nasopharyngeal swab. - study participants must be symptomatic with any covid-19 symptoms defined by the bahrain national protocol - onset of symptoms must be within 10 days prior to enrolment. - study participants must have the ability to give informed consent. - participants must be at minimum 21 years of age. - mild to moderate covid-19 disease defined as saturation equals to or more than 93% on room air or pao2:fio2 ratio more than 300 on enrolment.

inclusion criteria: - admitted covid-19 patients being treated as an in-patient at a hospital facility. - covid-19 diagnosis confirmed by pcr nasopharyngeal swab. - study participants must be symptomatic with any covid-19 symptoms defined by the bahrain national protocol - onset of symptoms must be within 10 days prior to enrolment. - study participants must have the ability to give informed consent. - participants must be at minimum 21 years of age. - mild to moderate covid-19 disease defined as saturation equals to or more than 93% on room air or pao2:fio2 ratio more than 300 on enrolment.

inclusion criteria: - admitted covid-19 patients being treated as an in-patient at a hospital facility. - covid-19 diagnosis confirmed by pcr nasopharyngeal swab. - study participants must be symptomatic with at least one of the following symptoms : oral temperature >37.8c, cough, shortness of breath or sore throat. - onset of symptoms must be less than 7 days prior to enrolment. - study participants must have the ability to give informed consent. - participants must be at minimum 21 years of age.

inclusion criteria: - admitted covid-19 patients being treated as an in-patient at a hospital facility. - covid-19 diagnosis confirmed by pcr nasopharyngeal swab. - study participants must be symptomatic with at least one of the following symptoms : oral temperature >37.8c, cough, shortness of breath or sore throat. - onset of symptoms must be less than 7 days prior to enrolment. - study participants must have the ability to give informed consent. - participants must be at minimum 21 years of age.